The full impact of the breakthrough therapy designation remains to be seen,but the financial stakes are high. Therefore, it is important to assess how P&MA planning practices need to be adapted to take advantage of a potential breakthrough designation. Re-evaluation of P&MA activities is prudent for any manufacturer hoping to secure big wins in the face of future break-through drug launches.